Product category:
Nucleic acid sequencing and synthesis
News Release from: Bio-Rad Laboratories
Edited by the Laboratorytalk Editorial
Team on 07 March 2007
Bio-Rad back in US stock exchange
compliance
After its recent appointment of Louis Drapeau to Bio-Rad's board of directors in late February, the American Stock Exchange has confirmed that Bio-Rad is in compliance with Amex listing rules
Drapeau will serve on the board's audit committee He replaces Philip Padou who passed away late last year
Drapeau will stand for election to the board along with Bio-Rad's other directors at the company's annual meeting on April 24, 2007.
Drapeau currently serves as chief financial officer and senior vice president of finance at Nektar Therapeutics.
Previously, he has served in several executive positions at BioMarin Pharmaceutical, and audit partner and managing partner of northern California audit and business consulting at Arthur Andersen.
Drapeau currently serves on the board of directors of Inflazyme Pharmaceuticals where he is the chair of the board's audit committee. Request free introductory details about products from Bio-Rad Laboratories ...
• Bio-Rad Laboratories: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
